WESTMINSTER, Colo., May 1 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH), today announced that it will report its 2007 first
quarter financial results on Tuesday, May 8, 2007, before the open of the
U.S. financial markets.
Paul L. Berns, President and Chief Executive Officer, and other members
of Allos' senior management will provide a company update and summary of
first quarter results via webcast and conference call on Tuesday, May 8,
2007 at 8:30 AM ET. The dial in number for U.S. residents to participate is
877-407-8031. International callers should dial 201-689-8031. Participants
should reference the Allos Therapeutics conference call. An audio replay of
the conference call will be available from 5 PM ET on Tuesday, May 8, 2007,
until 11:59 PM ET on Friday, May 18, 2007. To access the replay, please
dial 877-660-6853 (domestic) or 201-612-7415 (international); Replay pass
codes (both required for playback): account # 286; conference ID # 239702.
The webcast of this call will be available from the homepage and the
investors/media section of the Company's web site, http://www.allos.com and will
be archived for 30 days.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel antifolate currently under evaluation in a pivotal
Phase 2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic
agent, in a Phase 1 trial in patients with advanced solid tumors. For
additional information, please visit the Company's website at
http://www.allos.com.
Safe Harbor Statement
The 2007 first quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk Factors"
section of Allos' Form 10-K for the year ended December 31, 2006 and in
Allos' periodic reports on Form 10-Q and Form 8-K. Allos is providing the
information contained in the press release and conference call as of the
date of the release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Senior Manager, Corporate
Communications, +1-720-540-5227, jneiman@allos.com, or Derek
Cole, Vice President, Investor Relations, +1-720-540-5367,
dcole@allos.com, both of Allos Therapeutics, Inc.
|
